ReviewWorld journal of gastroenterology2014
Clinical management of advanced gastric cancer: the role of new molecular drugs.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05299476 (A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- The Utility of HER2 Overexpression in Prognosis of Gastric Cancer: A Systematic Review and Meta-Analysis Study.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis.Medicine · 2017Pooled it
- The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.Investigational new drugs · 2019Trial
- Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.Scientific reports · 2017Trial
- Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes.International journal of molecular sciences · 2025Review
- Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study.Frontiers in oncology · 2023Article
- Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.Annals of translational medicine · 2022Article
- FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?Life (Basel, Switzerland) · 2022Review
- CircRNAs as Potential Blood Biomarkers and Key Elements in Regulatory Networks in Gastric Cancer.International journal of molecular sciences · 2022Article
- Integrated analysis of whole genome and transcriptome sequencing in a young patient with gastric cancer provides insights for precision therapy.Oncology letters · 2020Article
- Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.Cancer management and research · 2020Article
- Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.Cancer science · 2019Article
- Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.Cancers · 2019Review
- Human chorionic gonadotropin promotes cell proliferation through the activation of c-Met in gastric cancer cells.Oncology letters · 2018Article
- Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Observational
- Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.Journal of translational medicine · 2018Article
- Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma.BMC complementary and alternative medicine · 2018Article
- MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1.Experimental and therapeutic medicine · 2018Article
- Knockdown of CCNO decreases the tumorigenicity of gastric cancer by inducing apoptosis.OncoTargets and therapy · 2018Article
- CCAAT/enhancer-binding protein α decreases the viability of gastric cancer cells.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States. Surgery represents the main approach for this disease but, notwithstanding the advances in surgical techniques, we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates. Despite the development of new drugs has significantly improved the effectiveness of chemotherapy, the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor. Recently, several molecular target agents have been investigated; in particular, trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients. New molecules targeting vascular epithelial growth factor, mammalian target of rapamycin, and anti hepatocyte growth factor-c-Met pathway are also under investigation, with interesting results. Anyway, it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results. In this paper we review the actual "scenario" of targeted treatments, also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma, discussing their efficacy and potential applications in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.